Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study
Journal of the National Comprehensive Cancer Network · 2026-11 · 24 (11)
DOI: 10.6004/jnccn.2026.7058 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-11. Verfasst von Dharmesh Gopalakrishnan und 13 weiteren Autor:innen. Beteiligte Einrichtung: 1Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Metastatic sarcomatoid renal cell carcinoma (msRCC) is an aggressive disease typically associated with poor outcomes following VEGF-targeted therapies. This study evaluated in real-world outcomes in patients with msRCC based on whether they received treatment with immune checkpoint inhibitors (ICIs).
Methods
We conducted a multi-institutional, retrospective study of patients who received systemic therapy for msRCC between July 2010 and June 2020. In total, 203 patients across 6 US academic centers were included. Patients were categorized into 2 groups based on whether they received ICIs: ICI+ (n=155) and ICI− (n=48). Overall survival (OS) was estimated using the Kaplan–Meier method and measured from the initiation of frontline systemic therapy. Treatment responses were evaluated by investigators at participating centers.
Results
After a median follow-up of 48.1 months, OS was significantly longer in the ICI+ group (median OS, 31.0 vs 7.6 months; hazard ratio [HR], 0.38; 95% CI, 0.26–0.56; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Roswell Park Comprehensive Cancer Center, Buffalo, NY.
- 2Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
- 3Medical College of Wisconsin Cancer Center, Milwaukee, WI.
- 4The Ohio State University Comprehensive Cancer Center, Columbus, OH.
- 5University of Michigan Rogel Cancer Center, Ann Arbor, MI.
- 6Duke Cancer Institute, Durham, NC.
Zitieren
APA
Gopalakrishnan, D., Fujiwara, Y., Collier, K. A., Park, J. J., Zaemes, J. P., Lam, E. T., Alaklabi, S., Jaeger, E. B., Barata, P. C., Kauffman, E. C., Atkins, M. B., Alva, A., Yang, Y., & George, S. (2026). Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study. Journal of the National Comprehensive Cancer Network, 24(11). https://doi.org/10.6004/jnccn.2026.7058
Vancouver
Gopalakrishnan D, Fujiwara Y, Collier KA, Park JJ, Zaemes JP, Lam ET, et al. Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study. Journal of the National Comprehensive Cancer Network. 2026;24(11). doi:10.6004/jnccn.2026.7058
BibTeX
@article{Gopalakrishnan2026,
author = {Gopalakrishnan, Dharmesh and Fujiwara, Yu and Collier, Katharine A and Park, Joseph J and Zaemes, Jacob P and Lam, Elaine T and Alaklabi, Sabah and Jaeger, Ellen B and Barata, Pedro C and Kauffman, Eric C and Atkins, Michael B and Alva, Ajjai and Yang, Yuanquan and George, Saby},
title = {Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {11},
doi = {10.6004/jnccn.2026.7058}
}
EUVIMED